S&P 500   4,668.07 (+1.60%)
DOW   35,232.03 (+0.95%)
QQQ   399.79 (+2.20%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
S&P 500   4,668.07 (+1.60%)
DOW   35,232.03 (+0.95%)
QQQ   399.79 (+2.20%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
S&P 500   4,668.07 (+1.60%)
DOW   35,232.03 (+0.95%)
QQQ   399.79 (+2.20%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
S&P 500   4,668.07 (+1.60%)
DOW   35,232.03 (+0.95%)
QQQ   399.79 (+2.20%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
NASDAQ:RETA

Reata Pharmaceuticals Stock Forecast, Price & News

$83.04
+1.64 (+2.01%)
(As of 11/29/2021 12:44 PM ET)
Add
Compare
Today's Range
$81.05
$84.09
50-Day Range
$81.40
$112.37
52-Week Range
$76.34
$160.41
Volume
6,275 shs
Average Volume
327,685 shs
Market Capitalization
$3.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.47
30 days | 90 days | 365 days | Advanced Chart
Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Reata Pharmaceuticals logo

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Headlines

Reata Pharmaceuticals (NASDAQ:RETA) Shares Gap Down to $89.00
November 24, 2021 |  americanbankingnews.com
Reata Pharmaceuticals (NASDAQ:RETA) Shares Gap Up to $88.10
November 19, 2021 |  americanbankingnews.com
Reata Pharmaceuticals (NASDAQ:RETA) Stock Price Down 6%
November 15, 2021 |  americanbankingnews.com
RETA Oct 2021 70.000 call
September 27, 2021 |  finance.yahoo.com
Reata Pharma Down 17% On Q2 Net Loss
August 10, 2021 |  nasdaq.com
Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat
August 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
267
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.02 million
Book Value
$7.03 per share

Profitability

Net Income
$-247.75 million
Net Margins
-2,020.49%
Pretax Margin
-2,026.45%

Debt

Price-To-Earnings

Miscellaneous

Free Float
26,199,000
Market Cap
$3.02 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

274th out of 1,392 stocks

Pharmaceutical Preparations Industry

119th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

Is Reata Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals
or view top-rated stocks.

How has Reata Pharmaceuticals' stock price been impacted by Coronavirus?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RETA shares have decreased by 47.4% and is now trading at $83.04.
View which stocks have been most impacted by COVID-19
.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Reata Pharmaceuticals
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) posted its earnings results on Monday, November, 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($2.32) by $0.35. The firm earned $7.40 million during the quarter, compared to analysts' expectations of $2.07 million. Reata Pharmaceuticals had a negative net margin of 2,020.49% and a negative trailing twelve-month return on equity of 81.91%. The company's revenue was up 428.6% compared to the same quarter last year. During the same period last year, the firm posted ($1.94) earnings per share.
View Reata Pharmaceuticals' earnings history
.

What price target have analysts set for RETA?

3 analysts have issued twelve-month target prices for Reata Pharmaceuticals' shares. Their forecasts range from $155.00 to $244.00. On average, they expect Reata Pharmaceuticals' share price to reach $211.67 in the next twelve months. This suggests a possible upside of 154.9% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:
  • J. Warren Huff, Chairman, President & Chief Executive Officer
  • Manmeet Singh Soni, Executive VP, Chief Operating & Financial Officer
  • W. Christian Wigley, Chief Scientific Officer, SVP & Founding Scientist
  • Colin J. Meyer, Chief Research & Development Officer, Executive VP (LinkedIn Profile)
  • Edmund Doherty, Vice President-Medical Affairs

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (11.66%), Invesco Ltd. (9.45%), BlackRock Inc. (5.83%), Franklin Resources Inc. (2.82%), Duquesne Family Office LLC (1.91%) and Camber Capital Management LP (1.88%). Company insiders that own Reata Pharmaceuticals stock include Colin John Meyer, Elaine Castellanos, James Warren Huff, Jason Douglas Wilson and Michael D Wortley.
View institutional ownership trends for Reata Pharmaceuticals
.

Which major investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Wellington Management Group LLP, Tolleson Wealth Management Inc., BlackRock Inc., HighTower Advisors LLC, Integral Health Asset Management LLC, ACT Capital L.L.C., and State of New Jersey Common Pension Fund D. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Colin John Meyer, and Elaine Castellanos.
View insider buying and selling activity for Reata Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Reata Pharmaceuticals stock?

RETA stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Camber Capital Management LP, Goldman Sachs Group Inc., Morgan Stanley, Caption Management LLC, Duquesne Family Office LLC, Citadel Advisors LLC, and Emerald Advisers LLC.
View insider buying and selling activity for Reata Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $83.04.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals has a market capitalization of $3.02 billion and generates $9.02 million in revenue each year. The company earns $-247.75 million in net income (profit) each year or ($7.73) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 267 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

Where are Reata Pharmaceuticals' headquarters?

Reata Pharmaceuticals is headquartered at 5320 LEGACY DRIVE, PLANO TX, 75024.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at (972) 865-2219 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.